K

Kilitch Drugs (India) Ltd
NSE:KILITCH

Watchlist Manager
Kilitch Drugs (India) Ltd
NSE:KILITCH
Watchlist
Price: 323.15 INR -0.46% Market Closed
Market Cap: 5.2B INR
Have any thoughts about
Kilitch Drugs (India) Ltd?
Write Note

Kilitch Drugs (India) Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kilitch Drugs (India) Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
K
Kilitch Drugs (India) Ltd
NSE:KILITCH
Total Liabilities & Equity
â‚ą2.6B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Liabilities & Equity
â‚ą467.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Liabilities & Equity
â‚ą346.6B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Liabilities & Equity
â‚ą881.2B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
11%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Liabilities & Equity
â‚ą150.9B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Liabilities & Equity
â‚ą119.6B
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kilitch Drugs (India) Ltd
Glance View

Market Cap
5.2B INR
Industry
Pharmaceuticals

Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.

KILITCH Intrinsic Value
251.63 INR
Overvaluation 22%
Intrinsic Value
Price
K

See Also

What is Kilitch Drugs (India) Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.6B INR

Based on the financial report for Sep 30, 2024, Kilitch Drugs (India) Ltd's Total Liabilities & Equity amounts to 2.6B INR.

What is Kilitch Drugs (India) Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
12%

Over the last year, the Total Liabilities & Equity growth was 9%. The average annual Total Liabilities & Equity growth rates for Kilitch Drugs (India) Ltd have been 8% over the past three years , 12% over the past five years .

Back to Top